Table 2.

Summary of pharmacogenetic cancer studies involving VEGF pathway: May 1990–July 2011

SiteLast name of first author(reference)Clinical trialDrugsNCountryGenes assessedPolymorphisms assessed, nSignificant results
VEGF pathway polymorphic predictive associations of survival and response
 BreastSchneider (9)YBevacizumab + paclitaxel vs. paclitaxel341United StatesVEGF KDR7VEGF −2578C>A, A associated with improved OS
VEGF −1154G>A, A associated with improved OS
 BreastEitenne-Grimaldi (10)YBevacizumab +/− taxane138FranceVEGF5VEGF +936C>T, T associated with improved TTP
 CRCLoupakis (11)NFOLFIRI + bevacizumab vs. FOLFIRI111ItalyVEGF4VEGF −460C>T, C associated with improved PFS
 CRCFormica (12)NFOLFIRI + bevacizumab40ItalyVEGF9VEGF −1154G>A, A associated with improved PFS
VEGF +405G>C, G associated with improved RR
 CRCZhang (13)YBevacizumab + cetuximab vs. cetuximab65United StatesVEGF KDR4
NRP1
 SCCHNArgiris (14)YPemetrexed and bevacizumab28United StatesVEGF3VEGF +405G>C, G associated with improved with improved OS, TTP but only 1 patient carried G/G
 OvarianSchulthesis (15)YBevacizumab + cyclophosphamide70United StatesNRP1 VEGF5NRP1 3′UTR C>T, T associated with poorer PFS
KDR
 OvarianSmerdel (16)YBevacizumab38DenmarkVEGF5
 MixedJain (17)YSorafenib + bevacizumab178United StatesKDR2
VEGF pathway polymorphic predictive associations of toxicity
BreastSchneider (9)YBevacizumab + paclitaxel vs. paclitaxel341United StatesVEGF KDR7VEGF +405G>C, G associated with increased HTNVEGF −460C>T, C associated with increased HTN
BreastEitenne-Grimaldi (10)YBevacizumab +/− taxane138FranceVEGF5VEGF +405G>C, C associated with increased toxicity
EsophagealSakaeda (18)N5-FU/cisplatin/radiation49JapanVEGF6VEGF −460C>T, C associated with increased chelitis
VEGF −1154G>A, A associated with increased chelitis and leukopenia
CRCLoupakis (11)NFOLFIRI + bevacizumab vs. FOLFIRI111ItalyVEGF4
CRCFormica (12)NFOLFIRI + bevacizumab40ItalyVEGF9
SCCHNArgiris (14)YPemetrexed and bevacizumab28United StatesVEGF3
OvarianSchulthesis (15)YBevacizumab + cyclophosphamide70United StatesNRP15
VEGF
KDR
MixedJain (17)YSorafenib + bevacizumab178United StatesKDR2KDR +1719A>T, T associated with increased toxicity
MixedSteeghs (19)YDanusertib63NetherlandsKDR7
FLT3
FLT4
MixedSteeghs (20)YTelatinib (phase I)33NetherlandsKDR5
FLT4

Abbreviations: CRC, colorectal cancer; FOLFIRI, 5-fluorouracil, folinic acid, irinotecan; 5-FU, 5-fluorouracil; HN, hypertension; N, no; NS, not statistically significant; SCCHN, squamous cell cancer of the head and neck; Y, yes.